2008
DOI: 10.1182/blood-2007-10-117531
|View full text |Cite
|
Sign up to set email alerts
|

Novel markers of normal and neoplastic human plasmacytoid dendritic cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

7
174
0
4

Year Published

2009
2009
2021
2021

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 202 publications
(185 citation statements)
references
References 127 publications
7
174
0
4
Order By: Relevance
“…The neoplastic cells are typically dim CD45 positive and may be TdT positive, compatible with blastic, immature cells (4,10,11). Although TdT expression is more commonly seen in precursor lymphoid neoplasms, in contrast to lymphoblastic leukemias, BPDCN will not exhibit lineage-specific markers such as CD3, CD19, CD79a, or cytoplasmic CD22, although expression of the T-cell associated antigens CD2 and CD7 has been reported (2).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The neoplastic cells are typically dim CD45 positive and may be TdT positive, compatible with blastic, immature cells (4,10,11). Although TdT expression is more commonly seen in precursor lymphoid neoplasms, in contrast to lymphoblastic leukemias, BPDCN will not exhibit lineage-specific markers such as CD3, CD19, CD79a, or cytoplasmic CD22, although expression of the T-cell associated antigens CD2 and CD7 has been reported (2).…”
Section: Discussionmentioning
confidence: 99%
“…Given that the neoplastic cells lack lineage-specific myeloid, B, or T-cell antigens, extensive immunophenotypic characterization must be employed to establish the diagnosis. The emergence of more specific PDC markers such as CD123 has made it possible to identify the PDC origin of BPDCN (10).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Th e plans are to continue his chemotherapy regimen with an eventual allogeneic bone marrow transplant. dendritic cells (2)(3)(4). Th is entity has been known under various names including agranular CD4 + natural killer (NK) cell leukemia, blastic NK-cell lymphoma, blastic NK leukemia, and agranular CD4 + , CD56 + hematodermic neoplasm.…”
Section: Case Reportmentioning
confidence: 99%
“…Low-level bone-marrow involvement is often seen at presentation or soon after [1,4,6,7]. Immunohistochemistry and flow cytometric analysis are essential tools for making the diagnosis and for evaluating new markers of disease; in particular, the adaptor protein CD2AP [8], BDCA-2 (CD303), and BDCA-4 (CD304) [1] were recently identified. Lymphadenopathy or splenomegaly or both are frequent.…”
Section: Diagnosis and Clinical Presentationmentioning
confidence: 99%